In particular, we elucidated the isolated effects of PD-1 inhibition on primary TIL and circulating immune cell populations in ccRCC, and we correlated the evolving immune milieu with anti-PD-1 response. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.